CVS MinuteClinic providers will use Medable's software platform to improve patient access, engagement and retention during clinical trials. Meanwhile, Thermo Fisher Scientific and Medidata Acorn AI announced a collaboration to develop an application that combines patient recruitment and site performance data for clinical trials.
We are extending our INVEST 2022 Pitch Perfect deadline to Feb 11, 11:59 p.m. ET to allow interested startups to apply to the 4 tracks - PharmaTech, Diagnostics 2.0, Care Coordination and Value-Based Care, and Remote Patient Monitoring and Smart Devices. Slots are going fast so we encourage all startups - particularly those interested to apply in the PharmaTech and Diagnostics tracks to apply immediately. Selected startups will get to pitch LIVE on stage in front of VC judges. Here's the agenda for the INVEST conference.
Endeavor BioMedicines aims to kill two birds with one stone—that stone being a small molecule drug. Taladegib targets a cell signaling pathway associated with both cancer and idiopathic pulmonary fibrosis, and the biotech will apply its Series B round toward clinical tests of the molecule on both fronts.
The National Association of Accountable Care Organizations would like to see higher participation of ACOs moving forward after a low number in the start of 2022, especially given the goal of all traditional Medicare patients in an accountable care model by 2030.
Even though 48% of hospitals surveyed had a shutdown related to an external hack or query in the last six months. a new report indicated that only 11% of hospitals listed cybersecurity as an area of high priority requiring investment.
WellSky will pilot its ReD technology at The OSU Wexner Medical Center with the goal to help heart failure patients avoid hospital readmissions. The technology allows providers to assess the fluid level in patients' lungs accurately, deemed as a symptom of worsening heart condition.
By Frank Vinluan Monday, February 7, 2022 12:32 PM
A rare disease drug that Sanofi added via its $11.6 billion Bioverativ acquisition is now approved for treating the blood disorder cold agglutinin disease. The regulatory nod makes the antibody drug the first approved treatment for this rare disease that leads to anemia.
No comments